Alkahest, Inc. news

Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease

Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases and a subsidiary of Grifols, today announced it will be delivering a presentation of data from a completed study of its therapeutic plasma fraction candidate, GRF6021, in subjects with Parkinson’s disease (PD) and cognitive impairment at the virtual 15th International Conference on Alzheimer’s and Parkinson’s Di

Mar. 8, yyyy

Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome

Grifols (MCE: GRF, MCE: GRF.P,NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced it has entered into a transaction to acquire the remaining equity of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis. No additional financing will be required.

The closing of the transaction is subject to the approval by the relevant antitrust authorities, and

Sep. 7, yyyy

Alkahest Announces Initiation of Phase 2 Study AKST1210-201 Exploring Treatment of Cognitive Impairment in End Stage Renal Disease Patients

Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced the initiation of a clinical study to explore the use of an extracorporeal medical device to remove excess Beta-2 microglobulin (B2M) from circulation for the treatment of cognitive impairment in patients undergoing hemodialysis for end stage renal disease (ESRD).

“A large proportion of individuals with end-stage rena

Jun. 1, yyyy

Alkahest Announces Initiation of Phase 2b Clinical Trial of AKST4290 in Patients with Treatment-Naïve Wet Age-Related Macular Degeneration

Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced the initiation of a phase 2b clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has dosed the first subject in AKST4290-205 (PHTHALO), which will assess the effects of AKST4290 on visual acuity with loading d

Feb. 10, yyyy

Alkahest Initiates a Phase 2 Clinical Trial of AKST4290 in Parkinson’s Disease with Funding from The Michael J. Fox Foundation

Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in a phase 2 clinical trial of AKST4290, an orally administered CCR3 inhibitor, for treatment of Parkinson’s disease. The trial, AKST4290-211 (TEAL), is funded in part by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and will evaluate the effect of AKST4290 on motor functi

Feb. 4, yyyy

Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of AKST4290 on Choroidal Blood Flow in Age-Related Macular Degeneration

Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the initiation of a phase 2 clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has treated the first patient in trial AKST4290-206 (STEEL) studying the effect of AKST4290 on choroidal blood flow (ChBF) in patients with neovascular age-related macular degeneration (AMD).

Dec. 17, yyyy

Alkahest to Present New Data from Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease at the Clinical Trials in Alzheimer’s Disease (CTAD) Conference

Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced an oral presentation of data from its phase 2a study ALK6019-201 in mild-to-moderate Alzheimer’s Disease at the 12th Clinical Trials on Alzheimer’s Disease from December 4 – 7, 2019 in San Diego. Presentation details can be found below.

Oral presentation:

Title:

Dec. 2, yyyy

Alkahest Announces Multiple Presentations at the Society for Neuroscience Annual Meeting

Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced upcoming presentations at the Society for Neuroscience (SFN) 49th Annual Meeting being held October 19 – October 23, 2019 at the McCormick Place Convention Center in Chicago. The Company will present data from recent studies demonstrating the rationale for study of its plasma fraction therapies for certain neurological and ag

Oct. 8, yyyy

Alkahest Initiates Phase 2 Clinical and Mechanistic Trial of Postoperative Recovery Following Primary Hip or Knee Arthroplasty

Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in AKST6021-211, a phase 2 clinical trial of its proprietary human plasma fraction, GRF6021, administered before and after primary hip or knee arthroplasty, to provide key insights into the immunomodulatory effects of the agent.

“This proof-of-concept

Aug. 19, yyyy